<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ). Livzon Pharmaceutical Group has completed a voluntary public tender offer for shares in Vietnam’s Imexpharm Corporation through its subsidiary LIANSGP Holding Pte. Ltd., after the offer period closed on 29 April 2026. Shareholders of Imexpharm tendered 104,545,781 shares at VND57,400 per share, below the original upper limit of 120,059,970 shares targeted in the bid. Following confirmation from the Vietnam Securities Depository and Clearing Corporation’s Ho Chi Minh City branch, the transfer of these shares has been finalized, giving Livzon an effective holding of 67.87% of Imexpharm’s registered capital and 67.88% of its voting shares. The acquisition secures Livzon a controlling stake in the Vietnamese listed drugmaker, strengthening its strategic foothold in Vietnam’s pharmaceutical market and consolidating its regional expansion efforts. The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page. More about Livzon Pharmaceutical Group Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, focused on the research, development, production and sale of medicines and related healthcare products. The group is expanding its presence in overseas markets, including Southeast Asia, as part of its broader growth and internationalization strategy. YTD Price Performance: -2.81% Average Trading Volume: 873,239 Technical Sentiment Signal: Hold Current Market Cap: HK$29.99B </div>

01513

159506

510660

513700

520690

562050

512010

512290

Livzon Pharmaceutical Group has completed a voluntary public tender offer for shares in Vietnam’s Imexpharm Corporation, acquiring a controlling stake of 67.87% of Imexpharm’s registered capital. The offer period closed on April 29, 2026, with shareholders tendering 104,545,781 shares at VND57,400 each. This acquisition strengthens Livzon's position in Vietnam's pharmaceutical market as part of its regional expansion strategy. The latest analyst rating for Livzon's stock (HK:1513) is a Sell, with a price target of HK$22.99.

Tip Ranks

LIVZON PHARMA

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

LIVZON GROUP

Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion